Imatinib Glenmark

Imatinib, the active ingredient in Imatinib Glenmark, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It targets malignant cells in chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor patients. GNH USA supplies Imatinib Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Glenmark is employed in the treatment of hematologic and solid tumours that depend on BCR‑ABL, c‑KIT or PDGFR signalling. - Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL‑driven proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission through blockade of the same kinase pathway. - Gastrointestinal stromal tumour (GIST): reduces tumour growth by targeting c‑KIT and PDGFR mutations.

Adverse reactions may occur with Imatinib Glenmark and are reported across clinical use.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet or face. - Fatigue: persistent tiredness not relieved by rest. - Diarrhoea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Cardiac failure: signs of reduced heart function such as dyspnoea. - Pulmonary hypertension: elevated pressure in lung arteries causing breathlessness.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Monitor blood counts: check complete blood count weekly during early treatment. - Assess liver function: perform hepatic panel before start and periodically thereafter. - Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac history. - Avoid strong CYP3A4 inhibitors: these can raise imatinib plasma levels. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Imatinib Glenmark can interact with several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase toxicity. - Antacids containing aluminum or magnesium: reduce absorption of imatinib. - Warfarin: concurrent use can enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may modestly raise drug levels. - Proton pump inhibitors: possible reduction in gastric acidity affecting absorption. - NSAIDs: combined use may increase gastrointestinal bleeding risk.